Ridgemont inks fourth deal since spin-out

The firm has purchased a majority stake in Gallus BioPharmaceuticals, its fourth acquisition since spinning out of Bank of America last August.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this